KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema -


- CEO transition supports...

Related Keywords

United Kingdom ,Washington ,United States ,Japan ,Benjaminl Palleiko ,Ben Palleiko ,Nasdaq ,Kalvista Pharmaceuticals Inc ,Drug Administration ,Exchange Commission ,Regulatory Agency ,Kalvista Pharmaceuticals ,Chief Executive Officer ,Fiscal Quarter ,Recent Business Highlights ,United Kingdom Medicines ,Innovation Passport ,United Kingdom Innovative Licensing ,Access Pathway ,Allergy Asthma ,Immunology Annual Meeting ,Fiscal Quarter Financial Results ,Vista Pharmaceuticals ,Securities Litigation Reform Act ,Consolidated Statement ,Consolidated Statements ,Markets ,